Texas border town doctor pleads with Biden: Halt ‘grossly irresponsible’ policies

Publisher's Picks
395

Translate to Spanish or other 102 languages!

Image for illustration purposes
Dr. Antonio Tony Falcon. Photo by TAFP

By Yael Halon | Fox News

- Advertisement -

Dr. Antonio Falcon, a highly regarded physician in the border town of Rio Grande City, Texas told Fox News that his practice has seen a significant “uptick in cases in the last couple of weeks.” Falcon’s region reported a 900% increase in the number of illegal detainees who tested positive for COVID-19 last month.

Coincidence? He thinks not.

“The uptick in cases locally is certainly linked to the number of those coming across the border who have already contracted the virus,” Falcon said. Read more, click here.

- Advertisement -

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Protecting Communities
Next article
An Overactive Sweet Tooth May Spell Trouble for Our Cellular Powerplants

More Articles

STHS McAllen Launches Naming Contest for Advanced Surgical Robot

Using advanced robotic technology to assist surgeons in performing complex procedures with enhanced precision, dexterity and control, robotic surgery represents one of the most significant advancements in modern medicine.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.

Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy

Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.
- Advertisement -